ArticleCardiovascular therapeutics2026
Asprosin Protects H9C2 Cells From Ferroptosis Following Hypoxia/Reoxygenation by Promoting Mitophagy.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcute myocardial infarction is a leading cause of death globally. Percutaneous coronary intervention is the primary treatment to restore blood flow to the affected myocardium, but reperfusion can cause myocardial injury, affecting the prognosis of patients with acute myocardial infarction. Asprosin (ASP) is a newly discovered adipokine whose role in myocardial protection requires further research.
methodsThe GSE240847 dataset was downloaded from the GEO database, and 511 ferroptosis-related genes were collected from the FerrDb database. Gene coexpression network analysis (WGCNA) was performed to identify coexpression modules associated with Fibrillin 1 (FBN1), followed by enrichment analysis. H9C2 cells were subjected to hypoxia/reoxygenation (H/R) and pretreated with ASP at different concentrations. The effects of ASP were determined by measuring cellular reactive oxygen species (ROS), Cell Counting Kit-8 (CCK-8), and lactate dehydrogenase (LDH) levels and assessing the expression of ferroptosis-related proteins, intracellular iron content, mitophagy-related proteins, and mitochondrial membrane potential.
resultsEnrichment analysis showed Gene Ontology (GO) terms linked to GTPase signaling, chromosome behavior, and cell stability. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis highlighted mitophagy and MAPK pathways in the FBN1 module. ASP cut ROS, boosted cell viability, and raised glutathione peroxidase 4 (GPX4)/solute carrier family 7 member 11 (SLC7A11) expression, upregulating glutathione and lowering iron particles dose dependently post H/R. It also increased PINK1 and stabilized mitochondria. A mitophagy inhibitor reduced these effects.
conclusionsThis study confirms the protective effects of ASP on myocardial cells after H/R injury and demonstrates that ASP can inhibit ferroptosis and promote mitophagy in myocardial cells during ischemia-reperfusion injury. The potential mechanism may involve ASP promoting PINK1-associated mitophagy in myocardial cells after H/R injury to inhibit ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.